^
Association details:
Biomarker:No biomarker
Cancer:Peripheral T-cell Lymphoma
Regimen:DHAP (cisplatin + cytarabine + dexamethasone injection)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Peripheral T-Cell Lymphomas...Preferred regimens...DHAP (dexamethasone, cytarabine, cisplatin) Second-line therapy and subsequent therapy for PTCL-NOS; EATL; MEITL....DHA (dexamethasone and cytarabine) + carboplatin was added as an option and the regimen was clarified as "DHA (dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)."